• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Targeting of nucleoprotein to chemokine receptors by DNA vaccination results in increased CD8+-mediated cross protection against influenza

tetano

Editor, Senior Moderator
Vaccine. 2015 Sep 17. pii: S0264-410X(15)01276-1. doi: 10.1016/j.vaccine.2015.08.094. [Epub ahead of print]
[h=1]Targeting of nucleoprotein to chemokine receptors by DNA vaccination results in increased CD8+-mediated cross protection against influenza.[/h] Baranowska M[SUP]1[/SUP], Hauge AG[SUP]2[/SUP], Hoornaert C[SUP]1[/SUP], Bogen B[SUP]3[/SUP], Gr?deland G[SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Vaccination is at present the most efficient way of preventing influenza infections. Currently used inactivated influenza vaccines can induce virus-neutralizing antibodies that are protective against a particular influenza strain, but hamper the induction of cross-protective T-cell responses to later infections. Thus, influenza vaccines need to be updated annually in order to confer protection against circulating influenza strains. This study aims at developing an efficient vaccine that can induce broader protection against influenza. For this purpose, we have used the highly conserved nucleoprotein (NP) from an influenza A virus subtype H7N7 strain, and inserted it into a vaccine format that targets an antigen directly to relevant antigen presenting cells (APCs). The vaccine format consists of bivalent antigenic and targeting units, linked via an Ig-based dimerization unit. In this study, NP was linked to MIP-1α, a chemokine that targets the linked antigen to chemokine receptors 1, 3 and 5 expressed on various APCs. The vaccine protein was indirectly delivered by DNA. Mice were vaccinated intradermally with plasmids, in combination with electroporation to enhance cellular uptake of DNA. We found that a single DNA vaccination was sufficient for induction of both antibody and T cell responses in BALB/c mice. Targeting of nucleoprotein to chemokine receptors enhanced T cell responses but not antibody responses. Moreover, a single dose of MIP1α-NP conferred protection in BALB/c mice against a lethal challenge with an H1N1 influenza virus. The observed cross-protection was mediated by CD8[SUP]+[/SUP] T cells.
Copyright ? 2015. Published by Elsevier Ltd.


[h=4]KEYWORDS:[/h] APC-targeting; Antigen presenting cells; Influenza; Nucleoprotein; T cells; Vaccine

PMID: 26387432 [PubMed - as supplied by publisher]
 
Back
Top Bottom